乳糖海藻糖是一种抗TREH的海藻糖类似物，在体内已被证明具有生物效应。研究发现，给予1%乳糖海藻糖的小鼠比给予1%海藻糖的小鼠显示出更显著的抗纤维化效果，包括减少胶原蛋白沉积和α-SMA免疫染色，以及抑制纤维形成基因的表达。

As the presidential election nears -- with just 21 days to go -- questions are swirling about the candidates' health. Over ...

Breast cancer treatments have changed dramatically over the past few decades. A one-size-fits-all removal of breasts through ...

Strong Memorial Hospital, Highland Hospital and other UR Medicine sites paused elective surgeries indefinitely, beginning Oct ...

A planned one-day work stoppage set for Tuesday by health care workers at the University of Michigan has been called off ...

While the Nobel-winning genome-editing technology CRISPR holds great promise, Duke’s Center for Advanced Genomic Technologies ...

With less than 12 hours before 2,700 Michigan Medicine hospital workers were scheduled to begin a one-day strike in Ann Arbor ...

重复扩增疾病（RED）是一组异质性疾病，主要影响神经系统，包括脆性X综合征和遗传性共济失调等。这类疾病很常见，全球患病率约为1/3000。然而，由于临床表现各异、地理分布不均以及技术限制，患者数量可能被低估。

The 2024 Nobel Prize in Medicine was awarded Monday to two American scientists, Victor Ambros and Gary Ruvkun, for their ...

北京时间2024年10月11日00时49分，Editas Medicine, Inc.（EDIT.us）股票出现异动，股价急速下挫5.09%。截至发稿，该股报2.96美元/股，成交量128.566万股， 换手率 1.56%，振幅4.49%。

周五,BMO Capital对Prime Medicine (NASDAQ:PRME)保持乐观态度,重申"跑赢大市"评级,目标价为19.00美元。该公司强调,这家生物技术公司最近宣布威尔逊病(WD)为其第二个主要项目,但市场对此基本忽视。据该公司称,由于未满足的医疗需求高,而Prime Medicine有潜力解决当前研究中基因疗法的局限性,WD代表了一个重要机会。 该公司采用脂质纳米粒(LNP)递 ...

周五，Leerink Partners维持了对Editas Medicine（NASDAQ:EDIT）的"市场表现"评级，目标价保持在$8.00不变。这一决定是在Editas Medicine最近宣布与DRI Healthcare Trust达成融资协议之后做出的。根据协议条款，Editas将获得$5700万的预付款，以换取来自与VRTX现有许可协议的未来许可费和付款。 该协议授权DRI Heal ...